Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""immunotherapy"" wg kryterium: Temat


Starter badań:

Tytuł:
Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
Autorzy:
Khvorost D; Department of Life Sciences, Los Angeles City College (LACC), 855 N. Vermont Ave., Los Angeles, CA 90029, USA.
Kendall B; Department of Life Sciences, Los Angeles City College (LACC), 855 N. Vermont Ave., Los Angeles, CA 90029, USA.
Jazirehi AR; Department of Life Sciences, Los Angeles City College (LACC), 855 N. Vermont Ave., Los Angeles, CA 90029, USA.; Department of Biological Sciences, College of Natural and Social Sciences, California State University, Los Angeles (CSULA), Los Angeles, CA 90032, USA.
Pokaż więcej
Źródło:
Cells [Cells] 2024 Apr 09; Vol. 13 (8). Date of Electronic Publication: 2024 Apr 09.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematologic Neoplasms*/therapy
Hematologic Neoplasms*/immunology
Immunotherapy, Adoptive*/methods
T-Lymphocytes*/immunology
Humans ; Antigens, CD19/immunology ; B-Lymphocytes/immunology ; Immunotherapy/methods ; Receptors, Antigen, T-Cell/immunology ; Receptors, Antigen, T-Cell/metabolism ; Receptors, Chimeric Antigen/immunology
Czasopismo naukowe
Tytuł:
CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours.
Autorzy:
Tang HKC; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Wang B; University of Cambridge, Trinity Hall, Cambridge CB3 9DP, UK.
Tan HX; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Sarwar MA; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Baraka B; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Shafiq T; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Rao AR; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Jun 08; Vol. 12 (12). Date of Electronic Publication: 2023 Jun 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunotherapy, Adoptive*/adverse effects
Neuroblastoma*/pathology
Humans ; Receptors, Antigen, T-Cell/metabolism ; T-Lymphocytes ; Immunotherapy ; CD3 Complex/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Biological Insight and Recent Advancement in the Treatment of Neuroblastoma.
Autorzy:
Rivera Z; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
Escutia C; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
Madonna MB; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
Gupta KH; Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.; Division of Surgical Oncology, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 May 09; Vol. 24 (10). Date of Electronic Publication: 2023 May 09.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunotherapy, Adoptive*/methods
Neuroblastoma*/genetics
Neuroblastoma*/therapy
Neuroblastoma*/metabolism
Infant, Newborn ; Child ; Humans ; N-Myc Proto-Oncogene Protein/genetics ; Immunotherapy/methods ; Tumor Microenvironment/genetics
Czasopismo naukowe
Tytuł:
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
Autorzy:
Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. .
Brentjens R; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Khleif SN; The Loop Immuno Oncology Laboratory, Georgetown University Medical School, Washington, DC, USA.
Odunsi K; University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
Rezvani K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruella M; Center for Cellular Immunotherapies and Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Sullivan RJ; Melanoma Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA.
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Apr 22; Vol. 21 (1), pp. 275. Date of Electronic Publication: 2023 Apr 22.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy*
Neoplasms*/therapy
Humans ; Immunotherapy, Adoptive ; T-Lymphocytes ; Biomarkers, Tumor ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Tumor therapeutic response monitored by telemetric temperature sensing, a preclinical study on immunotherapy and chemotherapy.
Autorzy:
Shao Q; Department of Mechanical Engineering, University of Minnesota, Minneapolis, USA. .
Lundgren M; Department of Radiology, University of Minnesota, Minneapolis, USA.
Lynch J; School of Medicine, University of Minnesota, Minneapolis, USA.
Jiang M; Department of Biomedical Engineering, University of Minnesota, Minneapolis, USA.
Mir M; School of Medicine, University of Minnesota, Minneapolis, USA.
Bischof J; Department of Mechanical Engineering, University of Minnesota, Minneapolis, USA.; Department of Biomedical Engineering, University of Minnesota, Minneapolis, USA.
Nelson M; Department of Radiology, University of Minnesota, Minneapolis, USA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 May 12; Vol. 13 (1), pp. 7727. Date of Electronic Publication: 2023 May 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunotherapy*
Melanoma*/pathology
Animals ; Temperature ; T-Lymphocytes/pathology ; Immunotherapy, Adoptive/methods ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies.
Autorzy:
Huang S; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wang X; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Wang Y; The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wang Y; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Fang C; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Wang Y; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.; School of Rehabilitation Sciences, Southern Medical University, Guangzhou, China.
Chen S; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chen R; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Lei T; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhang Y; The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xu X; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. .
Li Y; Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. .; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2023 May 06; Vol. 22 (1), pp. 80. Date of Electronic Publication: 2023 May 06.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunotherapy, Adoptive*/adverse effects
Receptors, Antigen, T-Cell*/genetics
Humans ; Immunotherapy
Czasopismo naukowe
Tytuł:
An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.
Autorzy:
Pereira R; Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Bergantim R; i3S-Instituto de Investigação e Inovação em Saúde, University of Porto, 4200-135 Porto, Portugal.; Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135 Porto, Portugal.; Clinical Hematology Department, Hospital Center of São João, 4200-319 Porto, Portugal.; Clinical Hematology Department, FMUP-Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 May 03; Vol. 25 (9). Date of Electronic Publication: 2024 May 03.
Typ publikacji:
Systematic Review; Journal Article; Meta-Analysis; Review
MeSH Terms:
Multiple Myeloma*/therapy
Multiple Myeloma*/immunology
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/methods
Receptors, Chimeric Antigen*/immunology
Humans ; Treatment Outcome ; Quality of Life ; Neoplasm Recurrence, Local/therapy ; Cytokine Release Syndrome/etiology
Czasopismo naukowe
Tytuł:
Surgery challenges and postoperative complications of lung cancer after neoadjuvant immunotherapy.
Autorzy:
Bai G; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chen X; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Peng Y; Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Ji Y; Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Bie F; Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Liu Y; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang Z; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Gao S; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 May; Vol. 15 (14), pp. 1138-1148. Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/surgery
Lung Neoplasms*/pathology
Postoperative Complications*/epidemiology
Postoperative Complications*/etiology
Neoadjuvant Therapy*/methods
Immunotherapy*/methods
Immunotherapy*/adverse effects
Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Pneumonectomy/adverse effects ; Pneumonectomy/methods ; Adult
Czasopismo naukowe
Tytuł:
Mathematical modeling of hypoxia and adenosine to explore tumor escape mechanisms in DC-based immunotherapy.
Autorzy:
Ghiyabi E; Department of Electrical Engineering, University of Zanjan, Zanjan, Iran.
Arabameri A; Department of Electrical Engineering, University of Zanjan, Zanjan, Iran. .
Charmi M; Department of Electrical Engineering, University of Zanjan, Zanjan, Iran.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 May 18; Vol. 14 (1), pp. 11387. Date of Electronic Publication: 2024 May 18.
Typ publikacji:
Journal Article
MeSH Terms:
Adenosine*/metabolism
Dendritic Cells*/immunology
Dendritic Cells*/metabolism
Immunotherapy*/methods
Tumor Escape*
Humans ; Tumor Microenvironment/immunology ; Animals ; Models, Theoretical ; Neoplasms/therapy ; Neoplasms/immunology ; Tumor Hypoxia ; Mice ; Hypoxia/metabolism
Czasopismo naukowe
Tytuł:
Neutrophils in Cancer immunotherapy: friends or foes?
Autorzy:
Huang X; College of Life Science, Yangtze University, Jingzhou, 434025, China.
Nepovimova E; Department of Chemistry, Faculty of Science, University of Hradec Králové, 500 03, Hradec Králové, Czech Republic.
Adam V; Department of Chemistry and Biochemistry, Mendel University in Brno, 613 00, Brno, Czech Republic.
Sivak L; Department of Chemistry and Biochemistry, Mendel University in Brno, 613 00, Brno, Czech Republic.
Heger Z; Department of Chemistry and Biochemistry, Mendel University in Brno, 613 00, Brno, Czech Republic.
Valko M; Faculty of Chemical and Food Technology, Slovak University of Technology, 812 37, Bratislava, Slovakia.
Wu Q; College of Life Science, Yangtze University, Jingzhou, 434025, China. .; Department of Chemistry, Faculty of Science, University of Hradec Králové, 500 03, Hradec Králové, Czech Republic. .
Kuca K; Department of Chemistry, Faculty of Science, University of Hradec Králové, 500 03, Hradec Králové, Czech Republic. .; Biomedical Research Center, University Hospital Hradec Kralove, 500 05, Hradec Kralove, Czech Republic. .; Andalusian Research Institute in Data Science and Computational Intelligence (DaSCI), University of Granada, Granada, Spain. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2024 May 18; Vol. 23 (1), pp. 107. Date of Electronic Publication: 2024 May 18.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Neutrophils*/immunology
Neutrophils*/metabolism
Neoplasms*/immunology
Neoplasms*/therapy
Neoplasms*/metabolism
Neoplasms*/pathology
Immunotherapy*/methods
Tumor Microenvironment*/immunology
Humans ; Animals ; Signal Transduction
Czasopismo naukowe
Tytuł:
Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis.
Autorzy:
Wang J; Department of Thoracic Surgery, the Second Hospital of Jilin University, Changchun City, China.
Lin J; Department of Hepatobiliary and Pancreatic Surgery, the Second Hospital of Jilin University, Changchun City, 130000, Jilin, China.
Wang R; Department of Operating Room, The Second Hospital of Jilin University, Changchun City, 130041, Jilin, China.
Tong T; Department of Thoracic Surgery, the Second Hospital of Jilin University, Changchun City, China.
Zhao Y; Department of Thoracic Surgery, the Second Hospital of Jilin University, Changchun City, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 May 17; Vol. 24 (1), pp. 603. Date of Electronic Publication: 2024 May 17.
Typ publikacji:
Journal Article; Systematic Review; Meta-Analysis
MeSH Terms:
Pyridines*/therapeutic use
Pyridines*/administration & dosage
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/pathology
Stomach Neoplasms*/mortality
Stomach Neoplasms*/therapy
Immunotherapy*/methods
Esophagogastric Junction*/pathology
Esophageal Neoplasms*/drug therapy
Esophageal Neoplasms*/therapy
Esophageal Neoplasms*/pathology
Esophageal Neoplasms*/mortality
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.
Autorzy:
Kim HM; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Kim KJ; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Lee K; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Yoon MJ; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Choih J; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.; Genuv US Subsidiary, CIC, 1 Broadway, Cambridge, MA, USA.
Hong TJ; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Cho EJ; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Jung HJ; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Kim J; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Park JS; Laboratory of Immunology, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS/FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Na HY; Laboratory of Immunology, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Heo YS; Department of Chemistry, Konkuk University, 120 Neungdong-Ro, Gwangjin-Gu, Seoul, 05029, Republic of Korea.
Park CG; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.; Laboratory of Immunology, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Park H; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.
Han S; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea.; Genuv US Subsidiary, CIC, 1 Broadway, Cambridge, MA, USA.
Bae D; Genuv Inc., B1 Shinyoung Building, 14 Gyeonghuigung-gil, Jongno-gu, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
BMC immunology [BMC Immunol] 2024 May 11; Vol. 25 (1), pp. 29. Date of Electronic Publication: 2024 May 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Programmed Cell Death 1 Receptor*/immunology
Programmed Cell Death 1 Receptor*/metabolism
Programmed Cell Death 1 Receptor*/antagonists & inhibitors
Cross Reactions*/immunology
Immunotherapy*/methods
Animals ; Humans ; Mice ; Hydrogen-Ion Concentration ; Neoplasms/immunology ; Neoplasms/therapy ; B7-H1 Antigen/immunology ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/antagonists & inhibitors ; Cell Line, Tumor ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Epitopes/immunology ; Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Mice, Inbred C57BL ; Female
Czasopismo naukowe
Tytuł:
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer.
Autorzy:
Wang M; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, Shandong Province, China.
Jing X; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, Shandong Province, China.
Chen F; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, Shandong Province, China.
Lu S; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, Shandong Province, China.
Sun Y; Department of Medical Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, 440 Jiyan Road, Jinan, 250117, Shandong Province, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 May 07; Vol. 24 (1), pp. 569. Date of Electronic Publication: 2024 May 07.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/immunology
Carcinoma, Non-Small-Cell Lung*/mortality
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/therapy
Carcinoma, Non-Small-Cell Lung*/pathology
Immune Checkpoint Inhibitors*/therapeutic use
Lung Neoplasms*/drug therapy
Lung Neoplasms*/mortality
Lung Neoplasms*/pathology
Lung Neoplasms*/immunology
Lung Neoplasms*/genetics
Lung Neoplasms*/therapy
Immunotherapy*/methods
Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Disease Progression ; Progression-Free Survival ; Adult ; Aged, 80 and over ; B7-H1 Antigen/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/antagonists & inhibitors
Czasopismo naukowe
Tytuł:
CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.
Autorzy:
Qu J; Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.; The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310003, P. R. China.
Wu B; Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.; The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310003, P. R. China.
Chen L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P.R. China.
Wen Z; Department of Cardiology, The First Affiliated Hospital, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.
Fang L; Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.; The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310003, P. R. China.
Zheng J; Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.; The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310003, P. R. China.
Shen Q; Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.; The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310003, P. R. China.
Heng J; Department of Clinical Pharmaceutical Research Institution, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, P. R. China. .
Zhou J; Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China. .; The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310003, P. R. China. .
Zhou J; Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, P. R. China.; The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Hangzhou, Zhejiang, 310003, P. R. China.
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 May 03; Vol. 43 (1), pp. 134. Date of Electronic Publication: 2024 May 03.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/immunology
Carcinoma, Non-Small-Cell Lung*/pathology
Receptors, CXCR6*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/immunology
Lung Neoplasms*/pathology
Lung Neoplasms*/metabolism
Lung Neoplasms*/genetics
Mucosal-Associated Invariant T Cells*/immunology
Mucosal-Associated Invariant T Cells*/metabolism
Immunotherapy*/methods
Immune Checkpoint Inhibitors*/therapeutic use
Immune Checkpoint Inhibitors*/pharmacology
Humans ; Male ; Female ; Middle Aged ; Aged ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism
Czasopismo naukowe
Tytuł:
Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy.
Autorzy:
Sukocheva OA; Department of Hepatology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia. .
Neganova ME; Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.; Arbuzov Institute of Organic and Physical Chemistry, Federal Research Center, Kazan Scientific Center, Russian Academy of Sciences, Kazan, 420088, Russian Federation.
Aleksandrova Y; Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.; Arbuzov Institute of Organic and Physical Chemistry, Federal Research Center, Kazan Scientific Center, Russian Academy of Sciences, Kazan, 420088, Russian Federation.
Burcher JT; College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL, 34211, USA.
Chugunova E; Arbuzov Institute of Organic and Physical Chemistry, Federal Research Center, Kazan Scientific Center, Russian Academy of Sciences, Kazan, 420088, Russian Federation.
Fan R; Department of Radiation Oncology, Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Tse E; Department of Hepatology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Sethi G; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117600, Singapore.
Bishayee A; College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL, 34211, USA. .
Liu J; Department of Radiation Oncology, Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. .
Pokaż więcej
Źródło:
Cell communication and signaling : CCS [Cell Commun Signal] 2024 May 02; Vol. 22 (1), pp. 251. Date of Electronic Publication: 2024 May 02.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/immunology
Neoplasms*/drug therapy
Neoplasms*/therapy
Neoplasms*/pathology
Immunotherapy*
Sphingolipids*/metabolism
Tumor Necrosis Factor-alpha*/metabolism
Signal Transduction*/drug effects
Humans ; Animals ; Drug Resistance, Neoplasm/drug effects ; Tumor Microenvironment/immunology ; Tumor Microenvironment/drug effects
Czasopismo naukowe
Tytuł:
Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
Autorzy:
Ren S; Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China.
Feng L; Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China.
Liu H; Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China.
Mao Y; Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China.
Yu Z; Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 May; Vol. 15 (14), pp. 1149-1163. Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/therapy
Gastrointestinal Microbiome*
Lung Neoplasms*/therapy
Immunotherapy*/methods
Animals ; Mice ; Humans ; Female ; Male ; Middle Aged ; Aged ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
Autorzy:
Mei SQ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Liu JQ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Huang ZJ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Luo WC; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Peng YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; School of Medicine South China University of Technology, Guangzhou, China.
Chen ZH; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Deng Y; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Xu CR; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 May; Vol. 15 (14), pp. 1119-1131. Date of Electronic Publication: 2024 Apr 01.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Immunotherapy*/methods
Tertiary Lymphoid Structures*/genetics
Humans ; Prognosis ; Female ; Male ; Biomarkers, Tumor/genetics
Czasopismo naukowe
Tytuł:
The potential and promise for clinical application of adoptive T cell therapy in cancer.
Autorzy:
Li Y; Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China.
Zheng Y; Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China.
Liu T; Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China.
Liao C; Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China.
Shen G; Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China. .
He Z; Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China. .; Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 May 01; Vol. 22 (1), pp. 413. Date of Electronic Publication: 2024 May 01.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/therapy
Neoplasms*/immunology
Immunotherapy, Adoptive*/methods
Humans ; T-Lymphocytes/immunology ; Animals ; Tumor Microenvironment/immunology ; Receptors, Chimeric Antigen/immunology ; Receptors, Antigen, T-Cell/immunology ; Receptors, Antigen, T-Cell/metabolism
Czasopismo naukowe
Tytuł:
Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in glioblastoma patients.
Autorzy:
Wang Y; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Wang Z; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Guo X; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Cao Y; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Xing H; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Wang Y; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Xing B; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Wang Y; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Yao Y; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Ma W; Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking UnionMedical College, Beijing, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7218.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Glioblastoma*/mortality
Glioblastoma*/immunology
Glioblastoma*/therapy
Immune Checkpoint Inhibitors*/therapeutic use
Neural Networks, Computer*
Immunotherapy*/methods
Programmed Cell Death 1 Receptor*/antagonists & inhibitors
B7-H1 Antigen*/antagonists & inhibitors
Humans ; Male ; Female ; Middle Aged ; Biomarkers, Tumor/genetics ; Brain Neoplasms/drug therapy ; Brain Neoplasms/genetics ; Brain Neoplasms/mortality ; Brain Neoplasms/immunology ; Aged ; Adult ; Prognosis ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
Autorzy:
Wu D; Clinical Medical College of Jining Medical University, Jining, Shandong Province, China.
Yang L; Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yan Y; Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jiang Z; Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Liu Y; Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Dong P; Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Taian, Jinan, Shandong, China.
Lv Y; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, National Key Laboratory of Advanced Drug Delivery and Release Systems, Jinan, Shandong, China.
Zhou S; Medical College, Wuhan University of Science and Technology, Wuhan, China.
Qiu Y; School of Nursing, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Yu X; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, National Key Laboratory of Advanced Drug Delivery and Release Systems, Jinan, Shandong, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7176.
Typ publikacji:
Systematic Review; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoadjuvant Therapy*/methods
Esophagogastric Junction*/pathology
Esophageal Neoplasms*/therapy
Esophageal Neoplasms*/pathology
Stomach Neoplasms*/therapy
Stomach Neoplasms*/pathology
Immunotherapy*/methods
Humans ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies